GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
November 27, 2023 08:35 ET
|
GRI Bio, Inc.
Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to...
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 15, 2023 08:05 ET
|
GRI Bio, Inc.
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024 Currently available treatments for IPF are...
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases
October 31, 2023 08:45 ET
|
GRI Bio, Inc.
Data presented at the 7th Annual Antifibrotic Drug Development (AFDD) Summit Company’s lead program, GRI-0621, has demonstrated ability to inhibit the activity of type I invariant NKT (iNKT) cells...
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference
October 19, 2023 08:45 ET
|
GRI Bio, Inc.
Findings demonstrate that the number of NKT cells positively correlates with the number of airway macrophages in IPF patients GRI Bio on track to launch Phase 2a biomarker...
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
October 17, 2023 08:35 ET
|
GRI Bio, Inc.
UK consortia brings together internationally recognized investigators in the UK's leading centers of excellence to carry out experimental and early phase research Translational work to be...
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference
October 11, 2023 09:05 ET
|
GRI Bio, Inc.
- Live moderated webcast with Marc Hertz, Chief Executive Officer of GRI Bio on Tuesday, October 24th at 11:00 AM ET LA JOLLA, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:...
GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions
October 05, 2023 08:45 ET
|
GRI Bio, Inc.
In several murine models of chronic inflammation and fibrosis, as well as in humans, it has been shown that iNKT cells are selectively activated in the disease setting Data supports GRI Bio’s...
GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 09:05 ET
|
GRI Bio, Inc.
LA JOLLA, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
August 23, 2023 09:00 ET
|
GRI Bio, Inc.
Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU Aardvark to leverage ADAIR formulation...
GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 08:05 ET
|
GRI Bio, Inc.
Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases On track to launch a Phase 2a biomarker study evaluating GRI-0621 for the treatment...